Cardiovascular Disease Prevention References

Last updated: 08 August 2024
  1. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2013 Jan;36(Suppl 1):S11-S66. doi: 10.2337/dc13-S011. Accessed 02 Aug 2013. PMID: 23264422
  2. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005 Dec;91(Suppl 5):v1-v52. doi: 10.1136/hrt.2005.079988. PMID: 16365341
  3. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007 Jan;30(1):162-172. doi: 10.2337/dc07-9917. PMID: 17192355
  4. Jellinger PS, Smith DA, Mehta AE, et al; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012 Mar-Apr;18(Suppl 1):1-78. https://www.ncbi.nlm.nih.gov. Accessed 4 Sep 2013. PMID: 22522068
  5. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011 Jun;8(6):e1001048. doi: 10.1371/journal.pmed.1001048. Accessed 28 Jun 2011. PMID: 21738449
  6. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007 Jul;45(2):158-165. doi: 10.1086/518849. PMID: 17578773
  7. Lackland DT, Elkind MS, D'Agostino R Sr, et al; American Heart Association Stroke Council; Council on Epidemiology and Prevention; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease. Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012 Jul;43(7):1998-2027. doi: 10.1161/STR.0b013e31825bcdac. PMID: 22627990
  8. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc. 2009 Aug;84(8):741-757. doi: 10.1016/S0025-6196(11)60525-9. PMID: 19648392
  9. Perk J, De Backer G, Gohlke H, et al; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012 Jul;33(13):1635-1701. doi: 10.1093/eurheartj/ehs092. PMID: 22555213
  10. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002 Jul;160(3):388-391. doi: 10.1161/01.cir.0000020190.45892.75. PMID: 12119259
  11. Redberg RF, Benjamin EJ, Bittner V, et al; American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; Preventive Cardiovascular Nurses Association. AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. Circulation. 2009 Sep;120(13):1296-1336. doi: 10.1161/CIRCULATIONAHA.109.192617. PMID: 19770388
  12. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011 Nov;124(22):2458-2473. doi: 10.1161/CIR.0b013e318235eb4d. PMID: 22052934
  13. Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ. 2010 Oct;182(15):1617-1623. doi: 10.1503/cmaj.091819. PMID: 20855479
  14. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009 Mar;150(6):396-404. doi: 10.7326/0003-4819-150-6-200903170-00008. PMID: 19293072
  15. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998 Oct;19(10):1434-1503. doi: 10.1053/euhj.1998.1243. PMID: 9820987
  16. International Task Force for Prevention of Coronary Heart Disease & International Atherosclerosis Society. Pocket guide to prevention of coronary heart disease. Germany; 2003 Jan:001-128
  17. Medical Services Commission. Cardiovascular disease - primary prevention. Toronto (ON); 2008 Mar:001-018.
  18. MedWormhttp://www.medworm.com/rss/index.php/Cardiology/7/http://www.medworm.com/rss/medicalfeeds/specialities/Cardiology.xml
  19. Noncommunicable Diseases and Mental Health, World Health Organization. Integrated management of cardiovascular risk. Report of WHO meeting, Geneva. WHO. http://whqlibdoc.who.int/. Jul 2012.
  20. Scottish Intercollegiate Guidelines Network (SIGN). Management of obesity. SIGN. http://www.sign.ac.uk. Feb 2010. Accessed 02 Aug 2013.
  21. World Health Organization (WHO). Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. WHO. http://whqlibdoc.who.int/. 2007.
  22. New Zealand Guidelines Group, National Heart Foundation of New Zealand & Stroke Foundation of New Zealand. The assessment and management of cardiovascular risk. Ministry of Health - Manatū Hauora. http://www.health.govt.nz/. Dec 2003.
  23. Ministry of Health (MOH) Singapore. Screening for cardiovascular disease and risk factors. MOH (Singapore). http://www.moh.gov.sg/. 2011.
  24. Ministry of Health Malaysia. Prevention of cardiovascular disease in women. Academy of Medicine Malaysia. http://www.acadmed.org.my. 2008.
  25. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun;129(25 Suppl 2):S49-S73. doi: 10.1161/01.cir.0000437741.48606.98. Accessed 05 May 2015. PMID: 24222018
  26. Jensen MD, Ryan DH, Apovian CM, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Nov 12, 2013. J Am Coll Cardiol. 2014 Jul;63(Suppl 25 Pt B):2985-3023. doi: 10.1016/j.jacc.2013.11.004. Accessed 05 May 2015. PMID: 24239920
  27. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun;129(25 Suppl 2):S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a. Accessed 05 May 2015. PMID: 24222016
  28. Piepoli MF, Hoes AW, Agewall S, et al; Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106. Accessed 29 Jun 2016. PMID: 27222591
  29. Ministry of Health Malaysia. Prevention of cardiovascular disease in women 2016. 2nd ed. Ministry of Health Malaysia. http://www.moh.gov.my. 2016. Accessed 21 Mar 2017.
  30. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016 Nov;32(11):1263-1282. doi: 10.1016/j.cjca.2016.07.510. Accessed 21 Mar 2017. PMID: 27712954
  31. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2017 Apr;23(4):479-497. doi: 10.4158/EP171764.GL. Accessed 23 Mar 2017. PMID: 28156151
  32. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2016 Jul;68(1):92-125. doi: 10.1016/j.jacc.2016.03.519. Accessed 21 Mar 2017. PMID: 27046161
  33. Siscovick DS, Barringer TA, Fretts AM, et al; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (Fish Oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017 Apr 11;135(15):e867-e884. doi: 10.1161/CIR.0000000000000482. Accessed 23 Mar 2017. PMID: 28289069
  34. St-Onge MP, Ard J, Baskin ML, et al; American Heart Association Obesity Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Meal timing and frequency: implications for cardiovascular disease prevention: a scientific statement from the American Heart Association. Circulation. 2017 Feb;135(9):e96-e121. doi: 10.1161/CIR.0000000000000476. Accessed 21 Mar 2017. PMID: 28137935
  35. Cheung BM, Cheng CH, Lau CP, et al. 2016 Consensus statement on prevention of atherosclerotic cardiovascular disease in the Hong Kong population. Hong Kong Med J. 2017 Apr;23(2):191-201. doi: 10.12809/hkmj165045. Accessed 01 Aug 2017. PMID: 28387202
  36. Dehghan M, Mente A, Zhang X, et al; Prospective Urban Rural Epidemiology (PURE) study investigators. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017 Nov 4;390(10107):2050-2062. doi: 10.1016/S0140-6736(17)32252-3. Accessed 07 Sep 2017. PMID: 28864332
  37. Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015 Jun 24;11:967-977. doi: 10.2147/TCRM.S84210. Accessed 07 Sep 2017. PMID: 26150723
  38. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-e248. doi: 10.1016/j.jacc.2017.11.006. Accessed 16 Nov 2017. PMID: 29146535
  39. Ministry of Health Malaysia, Academy of Medicine Malaysia and National Heart Association of Malaysia. Clinical practice guidelines on primary & secondary prevention of cardiovascular disease 2017. Academy of Medicine Malaysia. http://www.acadmed.org.my. 2017. Accessed 18 Dec 2017.
  40. Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: a review of contemporary guidance and literature. JRSM Cardiovasc Dis. 2017;6:1-9. doi: 10.1177/2048004016687211. Accessed 09 May 2018. PMID: 28286646
  41. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002. Accessed 29 Jan 2019. PMID: 30423391
  42. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678. Accessed 18 Mar 2019. PMID: 30879355
  43. Das SR, Everett BM, Birtcher KK et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018 Dec 18;72(24):3200-3223. doi: 10.1016/j.jacc.2018.09.020. Accessed 19 Feb 2019. PMID: 30497881
  44. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. ESC. http://www.escardio.org. 31 Aug 2019. Accessed 03 Mar 2023.
  45. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. ESC. http://www.escardio.org. 31 Aug 2019. Accessed 10 Sep 2019.
  46. Centers for Disease Control and Prevention (CDC). People with certain medical conditions. CDC. https://www.cdc.gov/. 03 Feb 2021. Accessed 22 Feb 2021.
  47. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation. 2020 May 19;141(20):1648-1655. doi: 10.1161/CIRCULATIONAHA.120.046941. Accessed 22 Feb 2021. PMID: 32200663
  48. Doupis J, Avramidis K. Managing diabetes during the COVID-19 pandemic. Eur Endocrinol. 2020 Oct;16(2):85–87. doi: 10.17925/EE.2020.16.2.85. PMID: 33117436
  49. Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: an expert panel position statement from HEART UK. Atherosclerosis. 2020 Nov;313:126-136. doi: 10.1016/j.atherosclerosis.2020.09.008. Accessed 18 Jan 2021. PMID: 33045618
  50. Ishigami J, Kou M, Ding N, Matsushita K. Cardiovascular disease and coronavirus disease 2019: epidemiology, management, and prevention. Curr Epidemiol Rep. 2021 Jan 02:1-8. doi: 10.1007/s40471-020-00261-2. PMID: 33425654
  51. Lim S, Bae JH, Kwon HS, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021 Jan;17(1):11-30. doi: 10.1038/s41574-020-00435-4. Accessed 22 Feb 2021. PMID: 33188364
  52. Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021 Mar;17(3):135-149. doi: 10.1038/s41574-020-00462-1. PMID: 33479538
  53. The European Society for Cardiology (ESC). ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. ESC. https://www.escardio.org. 10 Jun 2020. Accessed 22 Feb 2021.
  54. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. Accessed 15 Dec 2021. PMID: 34447992
  55. Visseren FLJ, Mach F, Smulders YM, et al; ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. Accessed 15 Dec 2021. PMID: 34458905
  56. The Task Force for the management of COVID-19 of the European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. Eur Heart J. 2022 Mar 14;43(11):1059-1103. doi: 10.1093/eurheartj/ehab697. Accessed 28 May 2022. PMID: 34791154
  57. Writing Committee; Lloyd-Jones DM, Morris PB, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 Aug 23;S0735-1097(22)05594-2. doi: 10.1016/j.jacc.2022.07.006. Accessed 01 Sep 2022. PMID: 36031461
  58. American Diabetes Association. Standards of care in diabetes - 2023. Diabetes Care. 2023 Jan;46(Suppl 1):S1-S280. https://diabetesjournals.org/. Accessed 05 Jun 2023. PMID: 36507639
  59. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021 Aug;37(8):1129-1150. doi: 10.1016/j.cjca.2021.03.016. Accessed 10 Jan 2023. PMID: 33781847
  60. Hennekens CH. Overview of primary prevention of cardiovascular disease. UpToDate. https://www.uptodate.com. 25 Aug 2022.
  61. Hennekens CH, Lopez-Sendon J. Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk. UpToDate. https://www.uptodate.com. 25 Oct 2022.
  62. Periodic Health Examination Task Force 2021. Philippine guidelines on periodic health examination. Screening for cardiovascular disease. Republic of the Philippines Department of Health. https://doh.gov.ph/. 2022.
  63. Lodoco highlights of prescribing information. U.S. Food & Drug Administration. https://www.accessdata.fda.gov. Jun 2023.
  64. Marx N, Federici M, Schutt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Aug 25;ehad192. doi: 10.1093/eurheartj/ehad192. Accessed 04 Sep 2023. PMID: 37622663
  65. National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE. https://www.nice.org.uk/guidance/ng238. 14 Dec 2023. Accessed 02 Apr 2024.